MarketInOut Stock Screener Log In | Sign Up
 

Humacyte Inc

NASDAQ • Healthcare • Biotechnology • Quote as of 07/02/2026
Humacyte Inc stock price and volume chart

Company Profile

IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization191.44 mln
Float196 mln
Earnings Date08/17/2026

Piotroski F-Score

2 / 9
Weak

Beneish M-Score

-3.17
Reliable

1-Year Forecast

2.05
Transformational upside

Relative Strength

3 / 100
Severely lagging

Debt / Equity

5.67
Extremely leveraged

ROE

-974
Deeply negative

Business Description

Humacyte, founded in 2004 and based in Durham, North Carolina, creates ready-to-use human tissue products that can be implanted into patients without triggering immune rejection. The company's core technology produces engineered blood vessels designed to repair, reconstruct, or replace damaged vasculature in a wide range of medical situations, from traumatic injuries and kidney dialysis needs to heart surgery and arterial disease. These vessels can also serve as a delivery mechanism for cell-based treatments, such as transplanting insulin-producing cells to help patients with Type 1 diabetes.

Key Fundamentals

EPS-0.63
ROE-974
RPS0.01
ROIC-157
ROA-78.73
EBITDA, mln-79.77
EV / EBITDA-2.61
EV / EBIT-2.39
Revenue, mln2.02
EV / Revenue103

Financial Strength

Altman Z-Score-10.33
Piotroski F-Score 2 / 9
Beneish M-Score-3.17
1-Year Target Price2.05
Short Ratio4.64
Short % of Float13.70

Price Performance & Relative Strength

Period Price Performance Relative Strength
1 Week 14.52% 92 / 100   
1 Month -48.92% 2 / 100   
2 Months -13.73% 17 / 100   
6 Months -29.7% 17 / 100   
1 Year -68.86% 8 / 100   



Disclaimer - Privacy Policy - Terms Of Service - Cookie Use Policy - FAQ - Contact Us